Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Prelude Therapeutics Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRT7732, ONCE DAILY ORAL SMARCA2 DEGRADER, CURRENTLY ENROLLING AT THE SEVENTH DOSING COHORT (125 MG); COMPANY TO PROVIDE AN UPDATE WITH PRELIMINARY CLINICAL DATA, INCLUDING PK/PD, SAFETY AND INITIAL CLINICAL ACTIVITY BY YEAR END 2025 PHASE 1 STUDY OF PRT3789, A ONCE WEEKLY IV SMARCA2 DEGRADER, HAS BEEN COMPLETED; COMPANY TO PROVIDE FINAL DATA BY YEAR END 2025 PRELUDE IS ADVANCING A DEVELOPMENT CANDIDATE FOR ITS ORAL KAT6A DEGRADER PROGRAM AND REMAINS ON TRACK TO FILE AN IND IN THE FIRST HALF OF 2026 CURRENT CASH RUNWAY INTO THE SECOND QUARTER OF 2026 WITH $77.3 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES AS OF JUNE 30, 2025 WILMINGTON, DEL., AUG. 14, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL DEVELOPMENT PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

PRELUDE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILMINGTON, DEL., JUNE 02, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, ANNOUNCED TODAY THAT THE COMPANY WILL PARTICIPATE IN TWO UPCOMING HEALTHCARE CONFERENCES IN JUNE.

PRELUDE THERAPEUTICS TO PARTICIPATE IN UPCOMING HEALTHCARE CONFERENCES

PRT3789 MONOTHERAPY AND COMBINATION WITH DOCETAXEL ESCALATION ENROLLMENT IS COMPLETE AND THE COMPANY PLANS TO PRESENT UPDATED RESULTS IN THE SECOND HALF OF 2025 ENROLLMENT OF THE PHASE 1 STUDY OF PRELUDE'S ONCE DAILY, ORAL SMARCA2 DEGRADER, PRT7732 IS ADVANCING RAPIDLY, AND AN INITIAL DATA UPDATE IS ANTICIPATED IN THE SECOND HALF OF 2025 CURRENT CASH RUNWAY INTO THE SECOND QUARTER OF 2026 WITH $103.1 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES AS OF MARCH 31, 2025 WILMINGTON, DEL., MAY 06, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL DEVELOPMENT PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

PRELUDE THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILMINGTON, DEL., MAY 01, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, ANNOUNCED TODAY THAT THE COMPANY WILL PARTICIPATE IN THE CITIZENS LIFE SCIENCES CONFERENCE TAKING PLACE IN NEW YORK ON MAY 7, 2025.

PRELUDE THERAPEUTICS TO PARTICIPATE IN CITIZENS LIFE SCIENCES CONFERENCE

PRECLINICAL DATA ELUCIDATING THE MECHANISM OF ACTION OF PRT3789, PRELUDE'S FIRST-IN-CLASS, HIGHLY SELECTIVE SMARCA2 DEGRADER CURRENTLY IN EARLY CLINICAL DEVELOPMENT

PRELUDE ANNOUNCES PRESENTATIONS AT 2025 AACR ANNUAL MEETING

PRT3789 HAS DEMONSTRATED CLINICAL PROOF-OF-CONCEPT THAT SELECTIVELY DEGRADING SMARCA2 IS GENERALLY SAFE AND HAS MONOTHERAPY ANTI-TUMOR ACTIVITY IN PATIENTS WITH SMARCA4-DEFICIENT, NON-SMALL CELL LUNG (NSCLC), GASTRIC AND ESOPHAGEAL CANCER

PRELUDE THERAPEUTICS REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES PROGRAM OUTLOOK FOR 2025

WILMINGTON, DEL., MARCH 05, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, ANNOUNCED TODAY THAT THE COMPANY WILL PARTICIPATE IN THE BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE IN MIAMI, FL ON MARCH 11, 2025.

PRELUDE THERAPEUTICS TO PARTICIPATE IN BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

 PRT2527 DEMONSTRATED ACTIVITY ACROSS A RANGE OF RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES, INCLUDING PATIENTS WHO RECEIVED PRIOR CAR-T THERAPY

PRELUDE THERAPEUTICS PRESENTS PRELIMINARY RESULTS OF PHASE 1 DOSE-ESCALATION STUDY OF PRT2527 AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES

WILMINGTON, DEL., NOV. 27, 2024 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, ANNOUNCED TODAY THAT THE COMPANY WILL PARTICIPATE IN THE CITIZENS JMP SECURITIES HEMATOLOGY AND ONCOLOGY SUMMIT, TAKING PLACE VIRTUALLY ON DECEMBER 2, 2024.

PRELUDE THERAPEUTICS TO PARTICIPATE IN CITIZENS JMP SECURITIES HEMATOLOGY AND ONCOLOGY SUMMIT

 INTERIM DATA FROM ONGOING TRIAL OF PRT3789 SHOWED ADDITIONAL CLINICAL ACTIVITY AT HIGHER DOSES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)

PRELUDE THERAPEUTICS PRESENTS NEW DATA FROM SMARCA DEGRADER PORTFOLIO AT THE 36TH EORTC-NCI-AACR SYMPOSIUM

PRT3789, A NOVEL, HIGHLY-SELECTIVE SMARCA2 DEGRADER IN PATIENTS WITH ADVANCED SOLID TUMORS WITH A SMARCA4 MUTATION PLENARY SESSION PRESENTATION: OCTOBER 24, 2024, 10:00 AM CEST (4:00 AM EST) PRT3789, A NOVEL, HIGHLY-SELECTIVE SMARCA2 DEGRADER IN PATIENTS WITH ADVANCED SOLID TUMORS WITH A SMARCA4 MUTATION PLENARY SESSION PRESENTATION: OCTOBER 24, 2024, 10:00 AM CEST (4:00 AM EST)

Prelude Therapeutics Incorporated

PRLD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Prelude Therapeutics Incorporated

PRLD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PRLD